GRA VentureLab company Clearside Biomedical gets $4 million venture capital investment
Atlanta-based startup, Clearside Biomedical, garnered an $4 million venture capital investment that will help advance its technology through the safety and efficacy clinical trials necessary to gain FDA approval. Based on technology developed by researchers at Georgia Tech and Emory University, the company is working on microinjection technology that will use hollow needles to precisely target therapeutics within the eye.
“We expect that targeting drug delivery within the eye will be helpful because we should be able to concentrate drugs at the disease sites where they need to act, and keep them away from other locations,” said Georgia Tech’s Mark Prausnitz, one of the collaborators on the project. “This could reduce side effects and possibly also decrease the dose required.” Prausnitz’s collaborator at Emory is Henry Edelhauser.
Between two and three million eye injections are made each year, many of them to treat age-related macular degeneration (AMD). The researchers believe that the microneedle-based technique could be useful for treating both AMD and glaucoma, as well as other ocular conditions related to diabetes.
In addition to grants through the GRA VentureLab program to advance the company’s microinjection technology, the basic research on which the company was founded received support from the Georgia Research Alliance in securing funding from the National Institutes of Health. Read more here>